Salvage chemotherapy followed by autologous stem cell transplantation using targeted busulfan for refractory diffuse large B-cell lymphoma with dialysis-dependent end-stage renal disease

A treatment strategy of salvage chemotherapy and autologous stem cell transplantation in relapsed or refractory DLBCL patients on hemodialysis has not yet been established. We conducted a pharmacokinetic analysis in a refractory DLBCL patient with end-stage renal disease, and successfully administered adjusted dosing of salvage chemotherapies and conditioning regimen in autologous stem cell transplantation without any adverse events.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research

Related Links:

Publication date: Available online 9 October 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Hajime Yasuda, Yutaka Tsukune, Tadaaki Inano, Yosuke Mori, Yasunori Ota, Norio Komatsu
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 9 October 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Andrew Tiu, Vinicius Jorge, Peter Moussa, Djeneba Audrey Djibo, Sorab Gupta, Onder Alpdogan, Claudia Dourado
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 9 October 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Ryujiro Hara, Makoto Onizuka, Sawako Shiraiwa, Kaito Harada, Yasuyuki Aoyama, Daisuke Ogiya, Masako Toyosaki, Rikio Suzuki, Sinichiro Machida, Ken Ohmachi, Yoshiaki Ogawa, Hiroshi Kawada, Shigeki Watanabe, Akira Miyajima, Ryota Masuda, Masayuki Iwazaki, Mikio Mikami, Takashi Koike, Hiroyuki Mochizuki, Kiyoshi Ando
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 8 October 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Hayder Saeed, Lubomir Sokol
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 8 October 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Kirill A. Lyapichev, Narittee Sukswai, Evgeniya Angelova, Marian J. Kersh, Sherry Pierce, Marina Konopleva, Nitin Jain, Elias J. Jabbour, Jeffrey L. Jorgensen, Sa A. Wang, L. Jeffrey Medeiros, Joseph D. Khoury, Sergej Konoplev
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 8 October 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Allison Grana, Natalia Gut, Kiersten Williams, Joseph Maakaron, Kyle Porter, Basem M. William, Sumithira Vasu, Sam Penza, Jonathan E. Brammer, Ayman Saad, Marcin Puto, Samantha M. Jaglowski, Julianna Roddy
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 18 September 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Damoun Safarpour, Krishnan Srinivasan, Marwah Farooqui, Connor Roth, Masood Ghouse
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 17 September 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Gopila Gupta, Tulika Seth, Vikas Garg, Richa Juneja, Manoranjan Mahapatra, Sudip Kumar Datta, Ashish Datt Upadhyay, Renu Saxena
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
We report the first case of long-term ibrutinib administration in a hemodialysis patient with leukemic non-nodal mantle cell lymphoma (L-NN-MCL) in which ibr utinib therapy was both safe and effective.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research
Extranodal NK/T cell lymphoma (ENKTL) is a rare type of mature T and NK neoplasm. It is more prevalent in Asia and Latin America where Epstein Barr Virus (EBV) is endemic and have been linked to the disease. Most studies have emerged from those two regions to evaluate best management options. There are no standards of care in the management due to lack of unified approach depending on the treatment region and availability of different therapy options. Several reviews have focused on the outcome of the different chemotherapy combinations.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Article Source Type: research
More News: Chemotherapy | Dialysis | Hematology | Hemodialysis | Leukemia | Lymphoma | Myeloma | Stem Cell Therapy | Stem Cells | Study | Transplants